CD8A and non-small cell lung carcinoma: In this study, the Univariate analysis showed that age, ATB administration, CD4+, CD8+ and CD16 + 56+ T cell levels, but not sex, smoking status, tumor pathological type, or D-Dimer, are associated with MFS in patients with stage III NSCLC (Table 10).